Monte Rosa Therapeutics, Inc. Common Stock (GLUE)
Monte Rosa Therapeutics, Inc. develops targeted protein degradation therapies aimed at treating difficult-to-drug diseases. Focused on innovative approaches, the company leverages its proprietary technologies to discover and develop novel therapeutics for unmet medical needs.
Company News
Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel AI-powered degraders for immune-mediated diseases, receiving $120 million upfront and potential milestone payments up to $5.7 billion.
Monte Rosa Therapeutics signed a collaboration agreement with Novartis to develop novel molecular glue degraders for immune-mediated diseases, receiving a $120 million upfront payment and potential milestone payments up to $5.7 billion.
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Analysts have high hopes for these three innovation companies in 2024.